Chicago—Customized dosing of first-line sunitinib is safe and feasible, providing better response rates and survival in patients with metastatic renal cell carcinoma (mRCC) compared with the standard dosing schedule, according to prospective, Phase II study results presented at the 2017 annual meeting of the American Society for Clinical Oncology (abstract 4514).
Increased exposure to sunitinib (Sutent, Pfizer) has been linked to better outcomes. The investigators theorized that patients